Skip to main content

Table 1 Characteristics of patients according to the level of blood uric acid

From: Obesity interacts with hyperuricemia on the severity of non-alcoholic fatty liver disease

 

All NAFLD

Normo-uricemia

Hyper-uricemia

P value

Numbers, n

557

424

133

 

Age (years)*

50.77 ± 13.66

52.09 ± 12.49

46.54 ± 16.20

< 0.001

Gender(male), n%

344 (61.8%)

265 (62.5%)

79 (59.4%)

0.521

BMI (kg/m2)*

26.99 ± 3.18

26.83 ± 3.04

27.51 ± 3.52

0.03

TG (mmol/L)*

2.37 ± 1.71

2.24 ± 1.60

2.76 ± 1.98

0.006

HDL-C (mmol/L)

1.06 ± 0.28

1.06 ± 0.28

1.07 ± 0.29

0.686

FPG (mmol/L)

7.04 ± 3.05

7.09 ± 3.03

6.88 ± 3.12

0.487

Obesity, n (%)

411 (73.8%)

306 (72.2%)

105 (78.9%)

0.121

Hypertriglyceridemia, n (%)*

341 (61.2%)

249 (58.7%)

92 (69.2%)

0.031

Low-HDL, n (%)

357 (64.1%)

272 (64.2%)

85 (63.9%)

0.960

Elevated fasting glucose, n (%)

342 (61.4%)

260 (61.3%)

82 (61.7%)

0.945

Elevated blood pressure, n (%)

260 (46.7%)

192 (45.3%)

68 (51.1%)

0.238

Metabolic syndrome, n (%)*

401 (72%)

296 (69.8%)

105 (78.9%)

0.041

CAP (dB/m)*

273.50 ± 28.99

269.78 ± 27.50

285.38 ± 30.50

< 0.001

ALT(IU/L)*

44.90 ± 43.31

39.20 ± 33.58

63.05 ± 62.08

< 0.001

FIB-4 index

1.35 ± 0.85

1.37 ± 0.79

1.30 ± 1.04

0.449

LSM (kPa)*

7.34 ± 3.17

7.09 ± 2.80

8.15 ± 4.05

0.005

Serious hepatic steatosis, n (%)*

321(57.6%)

225(53.1%)

96(72.2%)

< 0.001

Elevated ALT, n (%) *

193 (34.6%)

124 (29.2%)

69 (51.9%)

< 0.001

Advanced fibrosis n (%)

93 (16.7%)

67 (15.8%)

26 (19.5%)

0.312

  1. Continuous variables were shows as mean ± standard deviation, and categorical variables were summarized with frequencies and percentages
  2. BMI body mass index, TG triglyceride, HDL-C high-density lipoprotein cholesterol, FPG fasting plasma glucose, CAP controlled attenuation parameter, ALT alanine transaminase, LSM liver stiffness measurement
  3. *P < 0.05 after t-test or chi-square analysis